Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015

BMC Public Health

Table 2 Proton-pump inhibitor dispensing prevalence in 2015 by sex and age (%)

	< 16	16–24	25–44	45–64	> 65	Total
Men
Omeprazole	0.29	2.40	6.77	16.89	47.73	14.60
Pantoprazole	0.00	0.04	0.21	0.66	2.13	0.59
Lansoprazole	0.01	0.05	0.12	0.49	1.27	0.38
Rabeprazole	0.00	0.02	0.06	0.18	0.51	0.15
Esomeprazole	0.04	0.06	0.23	0.48	1.03	0.38
Total	0.32	2.53	7.19	18.23	51.36	15.69
Women
Omeprazole	0.31	3.56	7.99	20.04	53.13	19.00
Pantoprazole	0.01	0.10	0.26	0.84	2.02	0.73
Lansoprazole	0.01	0.09	0.13	0.67	1.74	0.59
Rabeprazole	0.00	0.01	0.08	0.28	0.69	0.24
Esomeprazole	0.01	0.13	0.22	0.73	1.27	0.53
Total	0.33	3.78	8.42	21.73	57.18	20.43
All
Omeprazole	0.30	2.96	7.35	18.40	50.78	16.78
Pantoprazole	0.01	0.07	0.23	0.75	2.06	0.66
Lansoprazole	0.01	0.07	0.13	0.58	1.54	0.48
Rabeprazole	0.00	0.02	0.07	0.23	0.61	0.20
Esomeprazole	0.03	0.09	0.23	0.60	1.17	0.45
Total	0.33	3.13	7.77	19.91	54.64	18.04

ISSN: 1471-2458